-
Posted by
Two Blokes Tue at 1:00 PM -
Filed in
Stock
-
2 views
Declares a strategic pivot to lead the post-patent immunotherapy combination era SEOUL, South Korea , May 13, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) today announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Penetrium\u2122 in combination with docetaxel, as part of a strategic redirection to focus on immunotherapy-based combinations. The company plans to resubmit an IND application within this month for a new trial combining its ECM-targeting agent, Penetrium\u2122, with immune checkpoint inhibitors.
